BeOne Medicines (ADR) (ONC)
Develops and commercializes oncology medicines through an in-house global model.
$367.64
vs last close+1.97 (+0.54%)
Something off on this page? Send us feedback.
Next report
Nov 5, 26
in 44 days
EPS estimate
$1.90
Revenue estimate
$1.75B
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$1.43$1.22$0.84$1.09$0.58$1.96$2.05Pending
Estimate−$0.88−$0.71$0.48$0.72$1.60$0.73$1.63$1.90
Surprise−62.5%+271.8%+75.0%+51.4%−63.7%+168.5%+25.8%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$1.13B$1.12B$1.32B$1.41B$1.50B$1.51B$1.71BPending
Estimate$1.04B$1.25B$1.44B$1.45B$1.47B$1.44B$1.62B$1.75B
Surprise+8.5%−10.4%−8.8%−2.7%+2.2%+5.4%+4.9%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | $4.87 | — | — |
| Sep 2028 | $3.72 | — | — |
| Jun 2028 | $3.47 | — | — |
| Mar 2028 | $2.91 | — | — |
| Dec 2027 | $3.10 | — | — |
| Sep 2027 | $2.39 | — | — |
| Jun 2027 | $2.45 | — | — |
| Mar 2027 | $2.11 | — | — |
| Dec 2026 | $1.63 | — | — |
| Nov 2026 | $1.90 | — | — |
| Aug 2026 | $1.63 | $2.05 | +25.8% |
| May 2026 | $0.73 | $1.96 | +168.5% |
| Feb 2026 | $1.60 | $0.58 | −63.7% |
| Nov 2025 | $0.72 | $1.09 | +51.4% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| Mar 2024 | |||
| Dec 2023 | |||
| Sep 2023 | |||
| Jun 2023 | |||
| Mar 2023 | |||
| Dec 2022 | |||
| Sep 2022 | |||
| Jun 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Sep 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Dec 2019 | |||
| Sep 2019 | |||
| Jun 2019 | |||
| Mar 2019 | |||
| Dec 2018 | |||
| Sep 2018 | |||
| Jun 2018 | |||
| Mar 2018 | |||
| Dec 2017 | |||
| Sep 2017 | |||
| Jun 2017 | |||
| Mar 2017 | |||
| Dec 2016 | |||
| Sep 2016 | |||
| Jun 2016 | |||
| Mar 2016 | |||
| Dec 2015 | |||
| Sep 2015 | |||
| Jun 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | $4.87 | — | — | $2.77B | — | — | — |
| Sep 2028 | $3.72 | — | — | $1.89B | — | — | — |
| Jun 2028 | $3.47 | — | — | $1.85B | — | — | — |
| Mar 2028 | $2.91 | — | — | $1.74B | — | — | — |
| Dec 2027 | $3.10 | — | — | $2.03B | — | — | — |
| Sep 2027 | $2.39 | — | — | $1.93B | — | — | — |
| Jun 2027 | $2.45 | — | — | $1.92B | — | — | — |
| Mar 2027 | $2.11 | — | — | $1.70B | — | — | — |
| Dec 2026 | $1.63 | — | — | $1.79B | — | — | — |
| Nov 5, 2026 | $1.90 | — | — | $1.75B | — | — | — |
| Aug 5, 2026 | $1.63 | $2.05 | +25.8% | $1.62B | $1.71B | +4.9% | +1.4% |
| May 6, 2026 | $0.73 | $1.96 | +168.5% | $1.44B | $1.51B | +5.4% | +5.3% |
| Feb 26, 2026 | $1.60 | $0.58 | −63.7% | $1.47B | $1.50B | +2.2% | −8.5% |
| Nov 6, 2025 | $0.72 | $1.09 | +51.4% | $1.45B | $1.41B | −2.7% | +3.4% |
| Aug 6, 2025 | |||||||
| May 7, 2025 | |||||||
| Feb 27, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Aug 7, 2024 | |||||||
| Mar 31, 2024 | |||||||
| Dec 31, 2023 | |||||||
| Sep 30, 2023 | |||||||
| Jun 30, 2023 | |||||||
| Mar 31, 2023 | |||||||
| Dec 31, 2022 | |||||||
| Sep 30, 2022 | |||||||
| Jun 30, 2022 | |||||||
| Mar 31, 2022 | |||||||
| Dec 31, 2021 | |||||||
| Sep 30, 2021 | |||||||
| Jun 30, 2021 | |||||||
| Mar 31, 2021 | |||||||
| Dec 31, 2020 | |||||||
| Sep 30, 2020 | |||||||
| Jun 30, 2020 | |||||||
| Mar 31, 2020 | |||||||
| Dec 31, 2019 | |||||||
| Sep 30, 2019 | |||||||
| Jun 30, 2019 | |||||||
| Mar 31, 2019 | |||||||
| Dec 31, 2018 | |||||||
| Sep 30, 2018 | |||||||
| Jun 30, 2018 | |||||||
| Mar 31, 2018 | |||||||
| Dec 31, 2017 | |||||||
| Sep 30, 2017 | |||||||
| Jun 30, 2017 | |||||||
| Mar 31, 2017 | |||||||
| Dec 31, 2016 | |||||||
| Sep 30, 2016 | |||||||
| Jun 30, 2016 | |||||||
| Mar 31, 2016 | |||||||
| Dec 31, 2015 | |||||||
| Sep 30, 2015 | |||||||
| Jun 30, 2015 |